Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
Cash from Investing Activities
Mayne Pharma Group Ltd
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash from Investing Activities
AU$473.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Cash from Investing Activities
-AU$530.5k
|
CAGR 3-Years
-122%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash from Investing Activities
-AU$211.5m
|
CAGR 3-Years
-3 179%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-171%
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cash from Investing Activities
-AU$16.7m
|
CAGR 3-Years
-902%
|
CAGR 5-Years
-332%
|
CAGR 10-Years
N/A
|
|
Probiotec Ltd
ASX:PBP
|
Cash from Investing Activities
-AU$14.4m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash from Investing Activities
AU$3.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Cash from Investing Activities?
Cash from Investing Activities
473.5m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Cash from Investing Activities amounts to 473.5m AUD.